These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 18555623)

  • 1. Advances in bone biology and new treatments for bone loss.
    Gallagher JC
    Maturitas; 2008 May; 60(1):65-9. PubMed ID: 18555623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Osteoporosis and RANKL signal].
    Nakamura M; Udagawa N
    Clin Calcium; 2011 Aug; 21(8):1149-55. PubMed ID: 21814019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Control of bone resorption by RANKL-RANK system].
    Harada S; Takahashi N
    Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANK/RANKL/OPG role in distraction osteogenesis.
    Pérez-Sayáns M; Somoza-Martín JM; Barros-Angueira F; Rey JM; García-García A
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May; 109(5):679-86. PubMed ID: 20163972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
    Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
    J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology of RANK, RANKL, and osteoprotegerin.
    Boyce BF; Xing L
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis.
    Hamdy NA
    Curr Opin Investig Drugs; 2007 Apr; 8(4):299-303. PubMed ID: 17458179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
    Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
    Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Osteoclastogenesis and bone resorption].
    Nakamura M; Nakamichi Y; Nakamura H; Udagawa N
    Nihon Rinsho; 2009 May; 67(5):889-96. PubMed ID: 19432105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Present and future of the treatment of osteoporosis with monoclonal antibodies].
    Fiter Aresté J
    Reumatol Clin; 2011 Sep; 7 Suppl 2():S8-12. PubMed ID: 21924213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
    Kostenuik PJ
    Curr Opin Pharmacol; 2005 Dec; 5(6):618-25. PubMed ID: 16188502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rank/Rankl/opg: literature review.
    Silva I; Branco JC
    Acta Reumatol Port; 2011; 36(3):209-18. PubMed ID: 22113597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases.
    Delmas PD
    J Clin Densitom; 2008; 11(2):325-38. PubMed ID: 18375161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin as a potential therapy for osteoporosis.
    Hamdy NA
    Curr Osteoporos Rep; 2005 Dec; 3(4):121-5. PubMed ID: 16303111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key roles of the OPG-RANK-RANKL system in bone oncology.
    Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.